Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Carboplatin 23Cisplatin 19pembrolizumab 14Paclitaxel 12Gemcitabine 12Pemetrexed 11130-nm albumin-bound paclitaxel 9Everolimus 8Cetuximab 8Fluorouracil 7Axitinib 6osimertinib 5durvalumab 5Sunitinib 5Radiotherapy 5Erlotinib Hydrochloride 5Docetaxel 5Cyclophosphamide 5Albumin-Bound Paclitaxel 5Sorafenib 4Radiation 4Nivolumab 4Ipilimumab 4vosaroxin 3Radiotherapy, Intensity-Modulated 3Octreotide 3Irinotecan 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3pralsetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma × PE regimen × Clear all
NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

AstraZeneca

Phase 3 Active not recruiting
328 enrolled 23 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡